In this second of two podcasts, an expert discuss decision making for subsequent line therapy for advanced gastric cancer, and review cases to illustrate practical considerations, followed by a question-and-answer session. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributor:

David Ilson, MD

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.